The FTC issued an administrative complaint to block Omnicare’s bid for a hostile acquisition of its biggest and only U.S. rival, PharMerica. Omnicare and PharMerica are long-term care pharmacies, which work with institutional providers like skilled nursing facilities. The FTC believes that the merger would allow Omnicare to raise the price of drugs for Medicare Part D because the number of skilled nursing facilities receiving services from Omnicare would “dramatically increas[e],” thereby also increasing Omnicare’s bargaining power to raise the price of drugs to Part D health plans.
Featured News
Michigan Loses Antitrust Case Accusing Oil Giants of Blocking Renewable Energy
Sep 22, 2026 by
CPI
EU Antitrust Chief Says European SpaceX Challenger Will Face Full Merger Scrutiny
Sep 22, 2026 by
CPI
Canada Competition Bureau, Empire Settle Grocery Property-Control Probe
Sep 22, 2026 by
CPI
DoorDash $131.5 Million Settlement Puts New Focus on Gig Economy Regulation
Sep 22, 2026 by
CPI
UN Chief Presses for Global AI Framework With Independent Oversight
Sep 22, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – National Security
Sep 22, 2026 by
CPI
National Security in U.S. Antitrust Enforcement: Toward a More Disciplined Framework
Sep 22, 2026 by
Rod Rosenstein & Timothy Finley
The Department of War’s M&A Review Guidance: What Companies in the Defense Industry Need to Know
Sep 22, 2026 by
Eric Stocking & Paul Ney
National Security, Resilience and the Boundaries of Merger Control
Sep 22, 2026 by
Beatriz Marques
National Security and Competition: Building Resilient Telecommunications Networks
Sep 22, 2026 by
Roslyn Layton